Sponsors / RNAC
RNAC

Cartesian Therapeutics

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
6Trials in this database
13Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)NCT04146051Cartesian TherapeuticsPhase 2Active not recruiting2026-01-05Actual
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyNCT04436029Cartesian TherapeuticsPhase 2Completed2022-02-18Actual
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyNCT04816526Cartesian TherapeuticsPhase 2Terminated2022-08-04Actual
Descartes-08 for Patients With Systemic Lupus ErythematosusNCT06038474Cartesian TherapeuticsPhase 2Active not recruiting2026-12-01Estimated
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisNCT06799247Cartesian TherapeuticsPhase 3Active not recruiting2026-12-30Estimated
Descartes-08 in Autoantibody MyositisNCT07391605Cartesian TherapeuticsPhase 2Recruiting2027-11Estimated

Latest recorded trial changes

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

NCT06799247 · Cartesian Therapeutics

· 4 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

100 participants (planned)

+ After

128 participants (actual)

Primary completion date changed

− Before

30 Nov 2026

+ After

30 Dec 2026

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source
Descartes-08 for Patients With Systemic Lupus Erythematosus

NCT06038474 · Cartesian Therapeutics

· 4 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

30 participants (planned)

+ After

6 participants (actual)

Primary completion date changed

− Before

1 Nov 2025

+ After

1 Dec 2025

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source